• Explore /
  • Poster
  • / Early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay as a predictive biomarker in early-phase immunotherapy (IO) clinical trials.

Early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay as a predictive biomarker in early-phase immunotherapy (IO) clinical trials.

Abstract Poster

Authors

null

Enrique Sanz Garcia

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Enrique Sanz Garcia , Sofia Genta , Xiaoxi Chen , Qiuxiang Ou , Daniel Vilarim Araujo , Albiruni Ryan Abdul Razak , Aaron Richard Hansen , Anna Spreafico , Hua Bao , Xue Wu , Lillian L. Siu , Philippe L. Bedard

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2546)

DOI

10.1200/JCO.2022.40.16_suppl.2546

Abstract #

2546

Poster Bd #

201

Abstract Disclosures

Similar Posters

First Author: Pei Shu

First Author: John D. Powderly

First Author: Glenn J. Hanna

First Author: Jordan Kardos